TARO-DEFERASIROX 125 MG
DEFERASIROX : 125 MG · DIN 02463520 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-DEFERASIROX?
TARO-DEFERASIROX 125 MG contains DEFERASIROX : 125 MG. It is listed in the Health Canada Drug Product Database under DIN 02463520, held by TARO PHARMACEUTICALS INC, supplied as TABLET FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 26-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02463520 |
|---|---|
| Brand name | TARO-DEFERASIROX |
| Generic / active ingredient | DEFERASIROX : 125 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 125 MG |
| Dosage form | TABLET FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | V03AC03 DEFERASIROX |
| AHFS class | 64:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Jun-2017 |
| Original market date | 2017-06-26 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V03AC03 DEFERASIROX. 36 of 45 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | DIN 02461544 |
| APO-DEFERASIROX | 250 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | DIN 02461552 |
| APO-DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | DIN 02461560 |
| APO-DEFERASIROX (TYPE J) | 180 MG | TABLET | APOTEX INC | MARKETED | DIN 02485273 |
| APO-DEFERASIROX (TYPE J) | 360 MG | TABLET | APOTEX INC | MARKETED | DIN 02485281 |
| APO-DEFERASIROX (TYPE J) | 90 MG | TABLET | APOTEX INC | MARKETED | DIN 02485265 |
| AURO-DEFERASIROX (TYPE J) | 180 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02527782 |
| AURO-DEFERASIROX (TYPE J) | 360 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02527790 |
| AURO-DEFERASIROX (TYPE J) | 90 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02527774 |
| EXJADE | 125 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02287420 |
Who else supplies DEFERASIROX worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEFERASIROX appears in 1125 registered pack listings across 15 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.